Navigation Links
Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
Date:5/29/2008

BRAINTREE, Mass., May 29 /PRNewswire-FirstCall/ -- Haemonetics Corporation and Octapharma AG announced today the signing of a multi-year supply contract appointing Haemonetics as Octapharma's preferred provider of plasma collection technology in the United States. Under the agreement, Octapharma will use Haemonetics' technology to separate plasma from donor blood at its U.S. plasma collection centers. Plasma is the source of numerous proteins used for drug development and therapeutic purposes. These proteins include albumin, clotting factors, and intravenous immunoglobulin ("IVIG").

Octapharma, a Swiss-based company, is an independent plasma fractionation specialist, the largest privately owned plasma products company in the world. One of the top global plasma fractionators, Octapharma reported fiscal 2006 sales of euro 752 million with 37% growth year over year and has averaged revenue growth of 20% since 1995. The company owns five state of the art fractionation facilities in Austria, France, Sweden, Germany, and Mexico.

"In order to meet the increasing demand for Octapharma bio-pharmaceutical products, a key focus of the company is to extend production capacities in all our facilities. Octapharma has already started its partial vertical integration of owning plasma centers in Europe and the U.S., and it is our goal to source 50% of the plasma needed from our own centers by 2010," said Karl Erik Clausen, Chief Financial Officer of Octapharma. "Through our U.S. subsidiaries, Plasma Procurement Services, Inc. will secure Octapharma's supply of source plasma in the United States and Octapharma is pleased to be expanding its relationship with Haemonetics."

Stephen Swenson, General Manager of Global Plasma for Haemonetics, said, "Octapharma is a premier global plasma collector and fractionator, and it is the fastest growing company in the industry. We have been extremely pleased with the results relating to the European agreement we signed with Octapharma last year and are delighted to be expanding our relationship into the U.S."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

CONTACT:

Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

fallon@haemonetics.com


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
4. Octapharma Joins Biotechnology Industry Organization
5. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
8. Favrille Announces Workforce Reduction
9. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
10. Genmab Announces 2008 First Quarter Results
11. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... , March 24, 2017 Agenus Inc. ... immune checkpoint antibodies and cancer vaccines, today announced participation ... 7 th  Annual William Blair and Maidstone Life Sciences ... Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert B. ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
Breaking Biology Technology:
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
Breaking Biology News(10 mins):